<DOC>
	<DOCNO>NCT00887120</DOCNO>
	<brief_summary>To study pharmacokinetics low-dose standard dose , lopinavir/ritonavir ARV PI naive HIV-1 infect Thai child . To study clinical immunological efficacy 48 week lopinavir/ritonavir PI naïve HIV-1 infect Thai child</brief_summary>
	<brief_title>Dose Reduction Lopinavir Children</brief_title>
	<detailed_description>In 2002 , Thai Ministry Public Health ( MOPH ) launch National Access Antiretroviral Program People live HIV/AIDS ( NAPHA ) aim provide treatment Thai patient need antiretroviral treatment . By end 2005 , 80,000 HIV-infected Thais treat NAPHA program , include 6,000 child . The antiretroviral treatment regimen consist three antiretroviral drug ( ARV ) . The first-line regimen use NAPHA mainly generic drug produce Thai government pharmaceutical organization ( GPO ) , include fixed-drug combination stavudine , lamivudine , nevirapine ( GPOvir ) ; fixed-drug combination zidovudine , lamivudine , nevirapine ( GPOvir-Z ) . Majority patient respond well first-line regimen ( 1,2 ) , however 15 % patient drug resistance first-line regimen require second-line regimen ( 3 ) . The protease inhibitor ( PIs ) use second-line regimen , however limitation term cost metabolic complication ( 4 ) . Lopinavir/ritonavir widely use protease inhibitor child high efficacy syrup formulation easy use small child . There evidence support recommend dose accord US-FDA EU guideline result much high plasma blood level Thai child . Data 19 Thai child demonstrate Cmin 5.9 mg/L compare 3.4 mg/L US child use dose ( minimum acceptable Cmin 1.0 mg/L ) ( 5,6 ) . There study HIVNAT019 , demonstrate acceptable LPV plasma concentration treatment outcome Thai HIV-infected adult use reduce dose LPV/r 266mg/66 mg compare standard dose 400mg/100mg ( 7 ) . Therefore , study pharmacokinetic low dose LPV/r Thai HIV-infected child important ass safety efficacy strategy . This lead appropriate ARV dose child reduce long-term adverse event , also reduce ARV cost .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Age 2 18 year old Documented positive test HIV1 infection PInaïve HIV RNA viral load &gt; 1,000 copy Written inform consent Active opportunistic infection Relevant history current condition , illness might interfere drug absorption , distribution , metabolism excretion . Use concomitant medication may interfere pharmacokinetics lopinavir/ritonavir Pregnancy lactate Inability understand nature extent study procedure require .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Second line treatment</keyword>
	<keyword>therapeutic drug monitoring</keyword>
	<keyword>Asia</keyword>
	<keyword>LPV</keyword>
	<keyword>child</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>To study pharmacokinetics low-dose standard dose , lopinavir/ritonavir Protease inhibitor ( PI ) - naive HIV-1 infect Thai patient .</keyword>
	<keyword>To study clinical immunological efficacy 48-weeks lopinavir/ritonavir-based antiretroviral therapy PI naive HIV-1 infect Thai patient .</keyword>
</DOC>